What is Medacist?
Headquartered in Cheshire, Connecticut, Medacist operates at the intersection of artificial intelligence and clinical pharmacy management. The company distinguishes itself as the sole holder of a U.S. patent in the discipline of drug diversion analytics. Its proprietary Genesis healthcare data platform serves as the backbone for a sophisticated suite of analytic services that utilize machine learning to monitor the entire lifecycle of pharmaceutical products. From initial procurement and storage to final administration by medical professionals, Medacist provides healthcare providers with the visibility required to detect anomalous patterns. This capability is vital for institutions aiming to mitigate the risks of drug abuse, ensuring compliance and patient safety through data-driven insights.
How much funding has Medacist raised?
Medacist has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Medacist
PPP
Public-Private Partnership
What's next for Medacist?
With this late-stage financing, Medacist is positioned to accelerate the deployment of its AI-driven solutions across a broader spectrum of the healthcare industry. The strategic focus will likely center on scaling the Genesis platform to integrate with increasingly complex electronic health record systems and expanding its footprint in large-scale hospital networks. As the regulatory landscape regarding controlled substance monitoring becomes more stringent, Medacist's ability to provide actionable intelligence will be a key driver for its continued growth. The company is expected to prioritize the enhancement of its predictive modeling capabilities, further refining its ability to identify potential diversion events before they escalate, thereby cementing its status as an indispensable partner for risk-averse healthcare organizations.
See full Medacist company page
